Global Search | Novartis

Hide Filters

Showing 2689 results

Press Release / Mar 22, 2024

Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)

Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy1-5 If…
Non-profit partnering for positive, sustainable social change
Donations
Media Library / Mar 01, 2024

Novartis radioligand therapy (RLT) manufacturing facility
Media Library / Mar 01, 2024

Radioligand therapy (RLT) production line
Media Library / Mar 01, 2024

Refrigeration room at a Novartis radioligand therapy (RLT) manufacturing facility
Media Library / Mar 01, 2024

Specialized equipment for the manufacture of radioligand therapy (RLT)
Media Library / Mar 01, 2024

Quality control for environmental monitoring in radioligand therapy (RLT) manufacturing
Press Release / Mar 05, 2024

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Shareholders approve 27th consecutive dividend increase to CHF 3.30 (+3.1%) per share for 2023; representing a 3.7% yield1 and approximately 58% payout of free cash flowShareholders confirm Joerg…
Press Release / Mar 05, 2024

Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire

Les actionnaires approuvent la 27e augmentation consécutive du dividende qui passe à CHF 3,30 (+3,1%) par action pour 2023 ; représentant un rendement de 3,7%1 et une distribution du…